Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49 Though the ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Shares of Pfizer Inc. PFE shed 3.49% to $21.84 Tuesday, on what proved to be an all-around poor trading session for the stock ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Investing in oil company ConocoPhillips (NYSE: COP) was one of the failures during this time, having suffered $1.53 billion loss by mid-2009 as oil prices dropped. Overall, Buffett was not only ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 7.31%, which has investors questioning if this is right time to ...

In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

We put performance trends for stocks, sectors, bonds, and funds into perspective, and offer outlooks for the next quarter.

Over the past five years, Pfizer's stock has gone from boom to bust. The pandemic sent the stock price soaring as demand for ...

Nurix Therapeutics, Inc.’s NRIX share price has dipped by 11.87%, which has investors questioning if this is right time to buy.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...